Navigation Links
Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis

icensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com

http://www.ReceptoPharm.com

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The publication of the ReceptoPharm article should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we
'"/>




Page: 1 2 3

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Inc. (NYSE: RMD ) today announced changes ... his position as Chief Executive Officer and President, and ... has appointed Dr. Peter C. Farrell, ResMed,s founder and ... and President, effective January 28, 2011.  Dr. Farrell will ...
... CardioGenics Holdings Inc. (OTC Bulletin Board: ... Merck Chimie SAS continue the commercialization process of ... while it is refining its encapsulation of the ... of magnetic beads coated with CardioGenics, proprietary silver-coating ...
Cached Medicine Technology:ResMed Inc. Announces Management Changes 2ResMed Inc. Announces Management Changes 3CardioGenics to Continue Commercialization of its Magnetic Beads with Merck Chimie SAS 2CardioGenics to Continue Commercialization of its Magnetic Beads with Merck Chimie SAS 3
(Date:7/9/2014)... A study published in the scientific journal ... Bonin, two researchers at Universit Laval, reveals that it ... method that involves rekindling pain so that it can ... means to alleviate chronic pain. , The researchers from ... universitaire en sant mentale de Qubec (IUSMQ) were inspired ...
(Date:7/9/2014)... the Keck School of Medicine of the University ... lacking a specific component of the immune system ... complication of infection. The discovery suggests that blocking ... in human autoimmune and hyper-inflammatory diseases such as ... study was published online on June 23 in ...
(Date:7/8/2014)... Memory Restoration has been awarded up to $15 million ... a four -year project aiming to help brain-injured people ... in neurosurgery, engineering, neurobiology, psychology and physics will collaborate ... in the brain. , Memory is the process in ... information, store it and retrieve it. Certain types of ...
(Date:7/8/2014)... A team of clinicians from Plymouth, UK, and Sydney, ... 10th July Australia) launched ACEmobile - a free-to-use app ... , ACEmobile is the first of its kind; an ... tool provides support through the whole process, meaning more ... out this type of assessment. Designed by clinicians for ...
(Date:7/8/2014)... 2014 In a study published yesterday in the ... La Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify ... currently affects over 200 million people world wide. , ... be divided into small sections or ,neighborhoods., Scientists can ... primed for gene production, by looking for a marker on ...
Breaking Medicine News(10 mins):Health News:Discovery of a new means to erase pain 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3Health News:New app widens opportunities for dementia assessments 2Health News:New app widens opportunities for dementia assessments 3Health News:LJI develops new approach to identify genes poised to respond in asthma patients 2
... INDIANAPOLIS and MINNEAPOLIS, Aug. 19 WellPoint, Inc. (NYSE: ... RedBr i ck Hea l th ... entered into a strategic collaboration to create a new, behavior-based wellness ... health plan customers. , , Through an upcoming ...
... , WINSTON-SALEM, N.C., Aug. 19 A ... red blood cells, is now broadly available for the first time ... While scientists have long known of the benefits of fish and ... has proven that the omega-3 fatty acids found in fish dramatically ...
... , MURRIETA, Calif., Aug. 19 Forterus Inc. (Pink ... alcohol rehabilitation and other behavioral healthcare services, announced today revenues increased ... ended June 30, 2009 compared to revenues of $1.04 million, or ... , Forterus announced net income of $32,921, or $0.002 ...
... , LANHAM, Md., Aug. 19 ... immunization awareness campaign, Protecting our Future: The COSHAR Foundation ... new materials, including updated information about autism and vaccines and ... now. , , Through this ...
... modern drug, but not the most common, experts say, , ... remedy called "thunder god vine" helps reduce inflammation in people ... is an extract of the medicinal plant Tripterygium wilfordii ... gong teng" -- and has been used for centuries to ...
... , , NASHVILLE, ... managed care market intelligence, reports that while commercial pharmacy ... July 2008 and January 2009, commercial pharmacy benefit enrollment ... only a two percent decline over the same time ...
Cached Medicine News:Health News:WellPoint Collaborates with RedBrick Health to Create Integrated, Behavior-Based Wellness and Incentives Programs 2Health News:WellPoint Collaborates with RedBrick Health to Create Integrated, Behavior-Based Wellness and Incentives Programs 3Health News:WellPoint Collaborates with RedBrick Health to Create Integrated, Behavior-Based Wellness and Incentives Programs 4Health News:New Omega-3 Blood Test: A Better Predictor of Coronary Heart Disease Than Cholesterol 2Health News:New Omega-3 Blood Test: A Better Predictor of Coronary Heart Disease Than Cholesterol 3Health News:New Omega-3 Blood Test: A Better Predictor of Coronary Heart Disease Than Cholesterol 4Health News:Forterus Inc. Posts Revenue, Net Income Gains 2Health News:COSHAR Foundation Enhances National Childhood Immunization Awareness Campaign 2Health News:Herb Shows Potential for Rheumatoid Arthritis 2Health News:Herb Shows Potential for Rheumatoid Arthritis 3Health News:Miami-Area Experienced Fewer Fluctuations in Pharmacy Benefit Enrollment Than Other Florida Markets 2
This legless table has adjustable height and round post. Pad sold separately....
This table has adjustable height, an integral leg, and blade post. Includes a standard 2" (5 cm) pad....
This table has adjustable height, round post, and universal clamp. Replacement 1" (5 cm) or 2" (2.5 cm) pad sold separately....
... An excellent choice for orthopedic procedures. ... width to 24" for the ... clamps quickly attach to any O.R. ... easy C-Arm access and stability. ...
Medicine Products: